Cell cycle proteins as promising targets in cancer therapy

By T. Otto, P. Sicinski. Nature Reviews. Cancer, 2017

1,675 citations recorded by the source corpus.

Subfields: Cell Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/85e0efdabcb92ffbcdd87fcc7354be4fe4ca6777

Citations in the corpus

• Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. (2017, neutral): “The D-type cyclins interact with either CDK4 or CDK6 to govern control of the G1/S transition (Otto and Sicinski, 2017).”
• Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance (2017, neutral): “Furthermore, treatment of multiple cancer cell lines with two different selective inhibitors of CDK4/6 kinase, palbociclib or ribociclib 8 , upregulated PD-L1 protein abundance and stability even in pRB knock-down cells (Fig.”